Baird analyst Joel Beatty initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharma Announces Board Member’s Departure
- Catalyst announces sub-licensee pharma launches FIRDAPSE in Japan
- Catalyst Pharma Highlights Growth in Rare Diseases Sector
- Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
- Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright